Latest News

Technology snags may limit adoption of current hybrid closed-loop insulin delivery system

NEW ORLEANS — Nearly one-third of participants in a study of first-time users of an “artificial pancreas” stopped using the system within a few months, primarily because of difficulties with the technology, according to data presented at The Endocrine Society Annual Meeting.
Those who continued using the Medtronic MiniMed 670G, the only FDA-approved hybrid closed-loop insulin delivery system on the market, experienced a mean decrease in HbA1c at 6 months, according to a presenter.
“The main takeaway message is that hybrid closed-loop technology is very challenging for

Source link

Related posts

Novel therapeutic approach for treatment of leukemia


Medical News Today: Some chiropractic treatments can harm eyesight


More than half of patients in pain management study took no opioids after operations


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy